These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 21288100)

  • 21. Response to open peer commentaries on "What is the best standard for the standard of care in clinical research?".
    van der Graaf R; van Delden JJ
    Am J Bioeth; 2009; 9(6-7):W7-8. PubMed ID: 19998101
    [No Abstract]   [Full Text] [Related]  

  • 22. A critique of clinical equipoise. Therapeutic misconception in the ethics of clinical trials.
    Miller FG; Brody H
    Hastings Cent Rep; 2003; 33(3):19-28. PubMed ID: 12854452
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The irrelevance of equipoise.
    Veatch RM
    J Med Philos; 2007; 32(2):167-83. PubMed ID: 17454421
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cluster randomized trials: another look.
    Macklin R
    Hastings Cent Rep; 2014; 44(1):37-43. PubMed ID: 24375386
    [No Abstract]   [Full Text] [Related]  

  • 25. Many randomized clinical trials may not be justified: a cross-sectional analysis of the ethics and science of randomized clinical trials.
    De Meulemeester J; Fedyk M; Jurkovic L; Reaume M; Dowlatshahi D; Stotts G; Shamy M
    J Clin Epidemiol; 2018 May; 97():20-25. PubMed ID: 29306063
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Vemurafenib (PLX4032): an orally available inhibitor of mutated BRAF for the treatment of metastatic melanoma.
    Heakal Y; Kester M; Savage S
    Ann Pharmacother; 2011 Nov; 45(11):1399-405. PubMed ID: 22028422
    [TBL] [Abstract][Full Text] [Related]  

  • 27. PLX4032 and melanoma: resistance, expectations and uncertainty.
    Roukos DH
    Expert Rev Anticancer Ther; 2011 Mar; 11(3):325-8. PubMed ID: 21417847
    [No Abstract]   [Full Text] [Related]  

  • 28. Ethical considerations for outcome-adaptive trial designs: a clinical researcher's perspective.
    Saxman SB
    Bioethics; 2015 Feb; 29(2):59-65. PubMed ID: 24547903
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Vemurafenib (RG67204, PLX4032): a potent, selective BRAF kinase inhibitor.
    Patrawala S; Puzanov I
    Future Oncol; 2012 May; 8(5):509-23. PubMed ID: 22646766
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Equipoise should be amended, not abandoned.
    van der Graaf R; van Delden JJ
    Clin Trials; 2011 Aug; 8(4):408-16. PubMed ID: 21746767
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical equipoise and risk-benefit assessment.
    Miller FG
    Clin Trials; 2012 Oct; 9(5):621-7. PubMed ID: 22777654
    [TBL] [Abstract][Full Text] [Related]  

  • 32. So-called "clinical equipoise" and the argument from design.
    Gifford F
    J Med Philos; 2007; 32(2):135-50. PubMed ID: 17454419
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Equipoise and the RCT.
    Braakhekke M; Mol F; Mastenbroek S; Mol BW; van der Veen F
    Hum Reprod; 2017 Feb; 32(2):257-260. PubMed ID: 28119447
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effectively targeting BRAF in melanoma: a formidable challenge.
    Fecher LA; Amaravadi R; Schuchter LM
    Pigment Cell Melanoma Res; 2008 Aug; 21(4):410-1. PubMed ID: 18710372
    [No Abstract]   [Full Text] [Related]  

  • 35. Randomized controlled trials of maternal-fetal surgery: a challenge to clinical equipoise.
    Rodrigues HC; van den Berg PP
    Bioethics; 2014 Oct; 28(8):405-13. PubMed ID: 23025329
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Upcoming strategies for the treatment of metastatic melanoma.
    Spagnolo F; Queirolo P
    Arch Dermatol Res; 2012 Apr; 304(3):177-84. PubMed ID: 22350184
    [TBL] [Abstract][Full Text] [Related]  

  • 37. What constitutes Clinical Equipoise?
    Helmy A; Timofeev I; Santarius T; Hutchinson P
    Br J Neurosurg; 2009; 23(5):564-5. PubMed ID: 19718548
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Clinical equipoise and systematic reviews of randomized controlled trials].
    Catalá-López F; González-Bermejo D; de la Fuente Honrubia C; Macías Saint-Gerons D
    Med Clin (Barc); 2015 Dec; 145(11):496-8. PubMed ID: 26004273
    [No Abstract]   [Full Text] [Related]  

  • 39. BRAF(V600) mutation levels predict response to vemurafenib in metastatic melanoma.
    Lebbé C; How-Kit A; Battistella M; Sadoux A; Podgorniak MP; Sidina I; Pages C; Roux J; Porcher R; Tost J; Mourah S
    Melanoma Res; 2014 Aug; 24(4):415-8. PubMed ID: 24933605
    [No Abstract]   [Full Text] [Related]  

  • 40. A closer look at the bad deal trial: beyond clinical equipoise.
    Jansen LA
    Hastings Cent Rep; 2005; 35(5):29-36. PubMed ID: 16295262
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.